Bayer Buys Into KRAS with $1.3bn Kumquat Deal

Bayer buys into KRAS cancer drug; Novartis immune therapy goes 3 for 3

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its study goal, while Biogen and Stoke began a key Phase 3 test.

Bayer buys into KRAS with $1.3bn Kumquat deal

Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer, via an alliance with San Diego biotech Kumquat

Bayer to pay $1.3 billion for Kumquat cancer drug in pharma push

Bayer to help fund development of an early-stage medicine for several types of cancer

Bayer to Pay $1.3 Billion for Kumquat Cancer Drug in Pharma Push

Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its struggling pharma division’s growth prospects.

Bayer and Kumquat Biosciences Enter $1.3B Collaboration to Advance Cancer Drug Candidate - USA Herald

Pharmaceutical giant Bayer and clinical-stage biotech company Kumquat Biosciences Inc. today announced an exclusive global license and collaboration agreement, under which Kumquat will receive up to $1.3B to develop and commercialize its pancreatic cancer-focused drug candidate. Under the terms of the agreement, Kumquat will receive funding that includes upfront payments, clinical and commercial milestones, and

Bayer, Kumquat Target KRAS Variant in Up-to-$1.3B+ Cancer Collaboration

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor through a collaboration that could generate up to $1.3 billion-plus for the San Diego biotech, while bolstering Bayer’s early precision oncology portfolio with a potential treatment for pancreatic, colorectal, and lung cancer, the companies said Tuesday. The collaboration comes after the FDA last month cleared Kumquat’s investigational new drug (IND) application…